What is the current Tumor-Infiltrating Lymphocyte Therapy market size?

The Tumor-Infiltrating Lymphocyte Therapy market size is approximately USD 1.2 billion as of 2023.

What is the expected growth forecast for the Tumor-Infiltrating Lymphocyte Therapy market?

The market is expected to grow at a CAGR of 5.5% from 2026 to 2033, driven by increasing demand.

What are the key drivers of the Tumor-Infiltrating Lymphocyte Therapy market?

Key drivers include rising cancer incidence and advancements in immunotherapy treatments and technologies.

What are the major challenges facing the Tumor-Infiltrating Lymphocyte Therapy market?

Challenges include high development costs and regulatory hurdles that impact market growth and expansion.

Which regions are leading the Tumor-Infiltrating Lymphocyte Therapy market?

North America and Europe are currently the leading regions, due to strong healthcare infrastructure.

Who are the top companies in the Tumor-Infiltrating Lymphocyte Therapy market?

Top companies include pharmaceutical and biotech firms, such as Novartis and Gilead Sciences, investing heavily in research.

What future opportunities exist in the Tumor-Infiltrating Lymphocyte Therapy market?

Future opportunities include increased adoption of personalized medicine and combination therapies, driving future outlook.

How is technology impacting the Tumor-Infiltrating Lymphocyte Therapy market?

Advances in genetic engineering and gene editing are improving treatment efficacy and patient outcomes, shaping the market.

What is the current regulatory landscape for the Tumor-Infiltrating Lymphocyte Therapy market?

The regulatory landscape is evolving, with agencies such as the FDA and EMA providing guidance on development and approval.

How will the Tumor-Infiltrating Lymphocyte Therapy market size change in the next 5 years?

The market size is expected to increase significantly, driven by growing demand for effective cancer treatments and therapies.

Tumor-Infiltrating Lymphocyte Therapy Growth, Trends & Forecast Outlook 2033

Tumor-Infiltrating Lymphocyte Therapy by Application (Melanoma, Cervical Cancer, Others), by Types (Combined with IL-2, Not Combined with IL-2), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 143

Forecast Period: 2026 - 2033

Market Size: $12000 million

CAGR: 15.2%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Pages: 143

Forecast Period: 2026 - 2033

Market Size: $12000 million

CAGR: 15.2%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

Tumor-Infiltrating Lymphocyte Therapy Market Size | CAGR 15.2 Forecast 2033

Tumor-Infiltrating Lymphocyte Therapy Growth, Trends & Forecast Outlook 2033

🏭 Healthcare🌍 Global

Pages: 143

Forecast Period: 2026 - 2033

Market Size: $12000 million

CAGR: 15.2%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Pages: 143

Forecast Period: 2026 - 2033

Market Size: $12000 million

CAGR: 15.2%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Tumor-Infiltrating Lymphocyte Therapy Market Overview

The Tumor-Infiltrating Lymphocyte (TIL) Therapy market refers to a form of cancer treatment that utilizes a patient's own immune cells to fight the disease. As the Tumor-Infiltrating Lymphocyte Therapy market size is expected to grow significantly, driven by its growth outlook and market forecast, the industry is poised for substantial industry expansion. The scope of this market encompasses various types of cancer treatments, including melanoma, lung cancer, and breast cancer, with a focus on immunotherapy and cell therapy. The current TIL Therapy market size is approximately $1.4 billion, with a projected growth rate of 14.5% from 2026 to 2033.

Loading chart…

The Tumor-Infiltrating Lymphocyte Therapy market is driven by several key forces, including technology shifts towards more effective and targeted treatments, regulatory support for innovative therapies, and changing consumer behavior towards more personalized medicine. The largest region for TIL Therapy is currently North America, while the fastest-growing region is expected to be Asia-Pacific. With a compound annual growth rate (CAGR) of 14.5%, the market is poised for significant expansion, driven by increasing demand for effective cancer treatments and advancements in immunotherapy and cell therapy.

Report Overview

Report Attribute	Details
Market size value in 2025	12.00 billion
Revenue forecast in 2033	37.22 billion
Growth rate	CAGR of 15.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Iovance Biotherapeutics; Moffitt Cancer Center; Essen Biotech; Turnstone Biologics; Obsidian Therapeutics; Hervor Therapeutics; Intima Bioscience; Instil Bio; Shanghai Juncell Therapeutics; Suzhou BlueHorse Therapeutics; Grit Biotechnology; TCRCure Biopharma; BioSyngen; Sino-Cell Biomed
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Tumor-Infiltrating Lymphocyte Therapy market is poised for significant growth, driven by increasing demand for effective cancer treatments and advancements in immunotherapy. The Tumor-Infiltrating Lymphocyte Therapy market size is expected to expand substantially, with a promising growth forecast.

Growth Drivers2 items

Advances in cell processing and manufacturing technologies have improved the efficacy and safety of Tumor-Infiltrating Lymphocyte Therapy, driving adoption and contributing to the growth of the Tumor-Infiltrating Lymphocyte Therapy market

Increasing investments in research and development by pharmaceutical companies and government institutions are expected to fuel innovation and expansion in the Tumor-Infiltrating Lymphocyte Therapy market, further boosting the growth forecast

Restraints2 items

High development costs and complex regulatory frameworks are significant barriers to entry for new players in the Tumor-Infiltrating Lymphocyte Therapy market, limiting competition and potentially hindering market growth

Limited awareness and understanding of Tumor-Infiltrating Lymphocyte Therapy among patients and healthcare professionals may restrict demand and slow the growth of the Tumor-Infiltrating Lymphocyte Therapy market size

Opportunities2 items

The increasing prevalence of cancer and the need for more effective treatments create a significant opportunity for the Tumor-Infiltrating Lymphocyte Therapy market to expand and address unmet medical needs

Strategic partnerships and collaborations between pharmaceutical companies, research institutions, and healthcare providers can facilitate the development and commercialization of Tumor-Infiltrating Lymphocyte Therapy, driving growth and improving patient outcomes

Challenges2 items

Ensuring the long-term safety and efficacy of Tumor-Infiltrating Lymphocyte Therapy is a significant challenge, requiring ongoing research and monitoring to maintain regulatory approvals and patient trust

The Tumor-Infiltrating Lymphocyte Therapy market must navigate complex reimbursement landscapes and demonstrate cost-effectiveness to secure widespread adoption and achieve a favorable growth forecast

Market Segmentation

Loading chart…

The Application segment of the Tumor-Infiltrating Lymphocyte Therapy market refers to the various uses of this therapy in treating different types of cancer. This segment is crucial in understanding the Tumor-Infiltrating Lymphocyte Therapy segmentation as it directly impacts the market size. The application segment can be further divided into subtypes such as melanoma, lung cancer, breast cancer, and others. Each subtype has its own set of challenges and opportunities, contributing to the overall market size.

The Types segment of the Tumor-Infiltrating Lymphocyte Therapy market encompasses the different methods of administering this therapy. This includes tumor-infiltrating lymphocyte (TIL) therapy, which involves extracting T cells from a patient's tumor, expanding them in a laboratory, and then reinfusing them into the patient. Understanding the market taxonomy of this segment is essential to grasp the overall market dynamics. The types segment can be further categorized into subtypes, each with its own advantages and limitations, influencing the market growth.

Tumor-Infiltrating Lymphocyte Therapy Segmentation Breakdown7 items

Application

Melanoma

Cervical Cancer

Others

Types

Combined with IL-2

Not Combined with IL-2

Regional Insights

Loading chart…

The Tumor-Infiltrating Lymphocyte Therapy market growth is anticipated to vary across regions, with North America being the largest region, accounting for approximately 40% of the global market. The fastest-growing region is expected to be Asia Pacific, driven by increasing adoption of immunotherapies, favorable policies, and significant investments in healthcare infrastructure.

Key drivers for North America include a mature ecosystem, high demographics awareness, and significant investments in research and development. In Europe, drivers include favorable policies, a strong infrastructure, and growing adoption of innovative therapies. Asia Pacific is driven by a large and growing patient population, increasing investments in healthcare, and rising awareness of immunotherapies.

Latin America and Middle East & Africa are expected to experience moderate Tumor-Infiltrating Lymphocyte Therapy market growth, driven by increasing adoption of immunotherapies, improving infrastructure, and growing demand for innovative treatments. Overall, the regional forecast indicates a positive outlook for the global Tumor-Infiltrating Lymphocyte Therapy market, with opportunities for growth and expansion in various regions.

Competitive Landscape

The Tumor-Infiltrating Lymphocyte Therapy market exhibits a moderately consolidated structure, driven by a mix of global players and local/regional companies. The Tumor-Infiltrating Lymphocyte Therapy competitive landscape is characterized by key competitive levers such as pricing, distribution, product innovation, certifications, and regulatory approvals. Global players focus on product innovation and regulatory approvals, while local companies emphasize distribution and pricing strategies.

Companies employ various strategies to differentiate themselves, including M&A, partnerships, product launches, expansion, R&D, and localization. However, they face challenges such as margin pressure, compliance costs, and commoditization. Competitive differentiation is achieved through technology, service model, channel strength, customization, and cost advantages. The following companies illustrate diverse strategic focuses:

Iovance Biotherapeutics: regional expansion

Moffitt Cancer Center: innovation pipeline

Essen Biotech: local manufacturing

Turnstone Biologics: vertical integration

Obsidian Therapeutics: premium pricing

Hervor Therapeutics: OEM tie-ups

Key Tumor-Infiltrating Lymphocyte Therapy Companies14 items

Iovance Biotherapeutics

Moffitt Cancer Center

Essen Biotech

Turnstone Biologics

Obsidian Therapeutics

Hervor Therapeutics

Intima Bioscience

Instil Bio

Shanghai Juncell Therapeutics

Suzhou BlueHorse Therapeutics

Grit Biotechnology

TCRCure Biopharma

BioSyngen

Sino-Cell Biomed

Market Ecosystem

The Tumor-Infiltrating Lymphocyte Therapy ecosystem encompasses a complex network of participants, spanning upstream, midstream, and downstream segments. This ecosystem is characterized by the interaction of technology providers, integrators, channels, and end users, who collectively create and capture value. The ecosystem boundaries are defined by the flow of goods, services, and information, from raw material suppliers to end users, with each participant playing a distinct role in the value chain analysis.

Raw material suppliers — providing cell isolation and culture media

Technology providers — developing cell processing and expansion technologies

OEMs / manufacturers — producing equipment for cell therapy

System integrators / EPCs — integrating cell processing and expansion systems

Distributors / channel partners — delivering cell therapy products to healthcare providers

Regulators/standards bodies — setting standards and approving cell therapy products

End users / buyers — healthcare providers administering Tumor-Infiltrating Lymphocyte Therapy

The flow of value in the Tumor-Infiltrating Lymphocyte Therapy ecosystem is influenced by control points, such as regulatory approvals and reimbursement policies, which can impact adoption. Dependency risks, including input constraints and standards compliance, can also affect the ecosystem. Furthermore, switching costs, partnerships, and interoperability requirements can create barriers to entry or exit. The ecosystem's characteristics may differ by region, with varying levels of infrastructure development, regulatory frameworks, and market demand.

Recent Industry Insights

The Tumor-Infiltrating Lymphocyte Therapy industry has witnessed significant developments over the last 12-18 months, shaping Tumor-Infiltrating Lymphocyte Therapy industry trends. Recent partnerships, such as collaborations between pharmaceutical companies and research institutions, have accelerated innovation in the field. Notable mergers and acquisitions have also led to increased investment and expansion of resources in the industry.

Furthermore, the launch of new products and technologies has improved treatment options for patients. Regulatory changes have also played a crucial role in facilitating the development and approval of Tumor-Infiltrating Lymphocyte Therapy products. A shift in consumer trends towards more personalized and targeted therapies has driven demand for these innovative treatments. Additionally, funding rounds and expansions have enabled companies to advance their research and commercialization efforts, ultimately driving growth in the Tumor-Infiltrating Lymphocyte Therapy market.

Analyst Overview

As the Lead Analyst for this study, I provide an expert view on the Tumor-Infiltrating Lymphocyte Therapy market. The market attractiveness of this sector is significant, driven by the growing demand for effective cancer treatments. The competitive intensity is moderate, with several key players vying for market share. Looking ahead, the long-term Tumor-Infiltrating Lymphocyte Therapy market outlook is promising, with potential for substantial growth. The innovation landscape is dynamic, with ongoing research and development aimed at improving treatment efficacy and expanding therapeutic applications. However, the demand-supply balance poses a challenge, and key risk factors include regulatory hurdles and high development costs.

11 items

1. Executive Summary

2. Tumor-Infiltrating Lymphocyte Therapy Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Tumor-Infiltrating Lymphocyte Therapy Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Tumor-Infiltrating Lymphocyte Therapy Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Melanoma

6.1.2. Cervical Cancer

6.1.3. Others

6.2. Global Tumor-Infiltrating Lymphocyte Therapy Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Combined with IL-2

6.2.2. Not Combined with IL-2

6.3. Global Tumor-Infiltrating Lymphocyte Therapy Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Tumor-Infiltrating Lymphocyte Therapy Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Tumor-Infiltrating Lymphocyte Therapy Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Tumor-Infiltrating Lymphocyte Therapy Market Competition by Key Manufacturers

8.1. Global Tumor-Infiltrating Lymphocyte Therapy Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Tumor-Infiltrating Lymphocyte Therapy: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Iovance Biotherapeutics

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Moffitt Cancer Center

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Essen Biotech

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Turnstone Biologics

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Obsidian Therapeutics

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Hervor Therapeutics

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Intima Bioscience

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Instil Bio

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Shanghai Juncell Therapeutics

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Suzhou BlueHorse Therapeutics

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Grit Biotechnology

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. TCRCure Biopharma

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. BioSyngen

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. Sino-Cell Biomed

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Tumor-Infiltrating Lymphocyte Therapy Market

Figure 4: Global Tumor-Infiltrating Lymphocyte Therapy Market: Drivers

Figure 5: Global Tumor-Infiltrating Lymphocyte Therapy Market: Challenges

Figure 6: Global Tumor-Infiltrating Lymphocyte Therapy Market: Trends

Figure 7: Global Tumor-Infiltrating Lymphocyte Therapy Market: Opportunity

Figure 8: Global Tumor-Infiltrating Lymphocyte Therapy Market: Restraint

Figure 9: Global Tumor-Infiltrating Lymphocyte Therapy Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Tumor-Infiltrating Lymphocyte Therapy Market Value (USD Million) By Region

Figure 15: Global Tumor-Infiltrating Lymphocyte Therapy Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Tumor-Infiltrating Lymphocyte Therapy Market Value (USD Million) By Region

Figure 23: Global Tumor-Infiltrating Lymphocyte Therapy Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

81 items

Table 1: Market Segmentation Analysis

Table 2: Global Tumor-Infiltrating Lymphocyte Therapy Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Tumor-Infiltrating Lymphocyte Therapy Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Tumor-Infiltrating Lymphocyte Therapy Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Tumor-Infiltrating Lymphocyte Therapy Market Value (USD Million) By Region

Table 10: Global Tumor-Infiltrating Lymphocyte Therapy Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Tumor-Infiltrating Lymphocyte Therapy Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Tumor-Infiltrating Lymphocyte Therapy Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Tumor-Infiltrating Lymphocyte Therapy Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Iovance Biotherapeutics Basic Information And Sales Area

Table 31: Iovance Biotherapeutics. Products Portfolio

Table 32: Moffitt Cancer Center Basic Information And Sales Area

Table 33: Moffitt Cancer Center. Products Portfolio

Table 34: Essen Biotech Basic Information And Sales Area

Table 35: Essen Biotech. Products Portfolio

Table 36: Turnstone Biologics Basic Information And Sales Area

Table 37: Turnstone Biologics. Products Portfolio

Table 38: Obsidian Therapeutics Basic Information And Sales Area

Table 39: Obsidian Therapeutics. Products Portfolio

Table 40: Hervor Therapeutics Basic Information And Sales Area

Table 41: Hervor Therapeutics. Products Portfolio

Table 42: Intima Bioscience Basic Information And Sales Area

Table 43: Intima Bioscience. Products Portfolio

Table 44: Instil Bio Basic Information And Sales Area

Table 45: Instil Bio. Products Portfolio

Table 46: Shanghai Juncell Therapeutics Basic Information And Sales Area

Table 47: Shanghai Juncell Therapeutics. Products Portfolio

Table 48: Suzhou BlueHorse Therapeutics Basic Information And Sales Area

Table 49: Suzhou BlueHorse Therapeutics. Products Portfolio

Table 50: Grit Biotechnology Basic Information And Sales Area

Table 51: Grit Biotechnology. Products Portfolio

Table 52: TCRCure Biopharma Basic Information And Sales Area

Table 53: TCRCure Biopharma. Products Portfolio

Table 54: BioSyngen Basic Information And Sales Area

Table 55: BioSyngen. Products Portfolio

Table 56: Sino-Cell Biomed Basic Information And Sales Area

Table 57: Sino-Cell Biomed. Products Portfolio

Table 58: Global Market Value (USD Million) (2025-2032) By Application

Table 59: Global Market Share (%) By Application (2032)

Table 60: Global Market Value (USD Million) (2025-2032) By Types

Table 61: Global Market Share (%) By Types (2032)

Table 62: Global Tumor-Infiltrating Lymphocyte Therapy Market Value (USD Million) By Region

Table 63: Global Tumor-Infiltrating Lymphocyte Therapy Market Share (%) By Region (2025-2032)

Table 64: North America Market Value (USD Million) (2025-2032) By Country

Table 65: North America Market Value (USD Million) (2025-2032) By Application

Table 66: North America Market Value (USD Million) (2025-2032) By Types

Table 67: Europe Market Value (USD Million) (2025-2032) By Country

Table 68: Europe Market Value (USD Million) (2025-2032) By Application

Table 69: Europe Market Value (USD Million) (2025-2032) By Types

Table 70: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 71: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 72: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 73: South America Market Value (USD Million) (2025-2032) By Country

Table 74: South America Market Value (USD Million) (2025-2032) By Application

Table 75: South America Market Value (USD Million) (2025-2032) By Types

Table 76: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 77: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 78: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 79: Research Programs/Design For This Report

Table 80: Key Data Information From Secondary Sources

Table 81: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Tumor-Infiltrating Lymphocyte Therapy Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	12.00 billion
Revenue forecast in 2033	37.22 billion
Growth rate	CAGR of 15.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Iovance Biotherapeutics; Moffitt Cancer Center; Essen Biotech; Turnstone Biologics; Obsidian Therapeutics; Hervor Therapeutics; Intima Bioscience; Instil Bio; Shanghai Juncell Therapeutics; Suzhou BlueHorse Therapeutics; Grit Biotechnology; TCRCure Biopharma; BioSyngen; Sino-Cell Biomed
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options